Cordavis Launches First Biosimilar: Novartis’ Hyrimoz to Compete with Humira
Swiss pharmaceutical giant Novartis (NYSE: NVS) unit Sandoz’s biosimilar product, Hyrimoz (adalimumab), which references AbbVie’s...
Microport EP Medtech’s Cryoablation Catheter and Equipment Approved as Innovative Devices in China
Shanghai Microport EP Medtech Co., Ltd has announced that its balloon type cryoablation catheter and...
CSPC Pharmaceutical’s Generic Entresto Approved in China for Heart Failure Treatment
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its generic version of Swiss...
Akeso Biopharma’s Ivonescimab Heads for Priority Review for NSCLC Treatment
China-based Akeso Biopharma (HKG: 9926) has announced that its bispecific antibody (BsAb) ivonescimab (AK112), targeting...
3SBio Inc. Reports H1 2023 Revenue Growth and Expansion in Digital Marketing
China-based 3SBio Inc. (HKG: 1530) has released its financial report for the first half of...
GSK’s Shingrix Proves 100% Efficacy in Phase IV Trial for Chinese Patients
UK-based pharmaceutical giant GSK plc (NYSE: GSK) has released efficacy data for its shingles vaccine,...
ImmuneOnco Biopharmaceuticals Launches IPO to Raise HKD 319 Million on Hong Kong Stock Exchange
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) is poised to raise HKD 319 million (USD...
Dizal Pharmaceutical’s Sunvozertinib Approved by China’s NMPA for NSCLC Treatment
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced that it has received market approval...
Hinova Pharmaceuticals’ HP518 for mCRPC Accepted for Review by China’s NMPA
Chengdu-based biotech company Hinova Pharmaceuticals Inc. (SHA: 688302) has announced that the National Medical Products...
Labway Clinical Laboratory Partners with 10x Genomics for Precision Medicine Advancements
Shanghai Labway Clinical Laboratory Co., Ltd., a leading provider of medical laboratory and pathological diagnostic...
Akeso Biopharma’s Ebdarokimab (AK101) NDA Accepted for Review by China’s CDE
China-based Akeso Biopharma (HKG: 9926) has announced that the New Drug Application (NDA) for its...
Beijing Drafts Regulations for Internet Diagnosis and Treatment, Prohibits AI Prescriptions
The Beijing Municipal Health Commission has released the “Implementation Measures for Internet Diagnosis and Treatment...
Innovent Biologics Reports 20.6% YOY Revenue Growth in H1 2023 Financials
China-based Innovent Biologics Inc., (HKG: 1801) has released its financial results for the first half...
Eli Lilly’s Retevmo Meets Primary Endpoint in Phase III Trial for RET-mutant Medullary Thyroid Cancer
Eli Lilly (NYSE: LLY) has announced that its Phase III trial for the RET kinase...
FDA Grants Priority Review to Pfizer and Astellas’ Xtandi for High-Risk Prostate Cancer
The US Food and Drug Administration (FDA) has granted priority review status to the submission...
Scott-Moncrieff & Associates Preparing 50 Cases Against AstraZeneca Over Vaccine Concerns
Scott-Moncrieff & Associates, a UK-based law firm, has disclosed that it is preparing nearly 50...
Nanjing F&S Pharmatech Secures First Generic Approval for Novartis’s Entresto in China
Nanjing F&S Pharmatech Co., Ltd, a China-based pharmaceutical company, has announced that it has received...
WuXi Biologics Reports 17.8% Revenue Growth and Expands Service Scope in H1 2023
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has released its...
Johnson & Johnson Completes Spinoff of Kenvue as Independent Company
Global healthcare giant Johnson & Johnson (J&J, NYSE: JNJ) has completed the separation of its...
Everest Medicines Reports Q1 2023 Revenue Growth and Pipeline Progress
China-based Everest Medicines (HKG: 1952) has announced its financial and corporate update for the first...